Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone972-9974-1444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees28
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
CELLECT BIOTECH/S (NASDAQ:APOP) Frequently Asked Questions
What is CELLECT BIOTECH/S's stock symbol?
CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP."
How were CELLECT BIOTECH/S's earnings last quarter?
When is CELLECT BIOTECH/S's next earnings date?
What price target have analysts set for APOP?
1 Wall Street analysts have issued 1-year target prices for CELLECT BIOTECH/S's shares. Their predictions range from $12.00 to $12.00. On average, they anticipate CELLECT BIOTECH/S's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 1,614.3% from the stock's current price. View Analyst Price Targets for CELLECT BIOTECH/S.
What is the consensus analysts' recommendation for CELLECT BIOTECH/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELLECT BIOTECH/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELLECT BIOTECH/S.
What are Wall Street analysts saying about CELLECT BIOTECH/S stock?
Here are some recent quotes from research analysts about CELLECT BIOTECH/S stock:
- 1. According to Zacks Investment Research, "Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. " (1/3/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We value Cellect based on a discounted cash flow (DCF) approach that assigns a total value of $120M to Cellect’s platform. Our valuation translates into a price per ADS of $14.00, taking into account roughly 8.8M fully-diluted ADSs outstanding as of mid-2019." (8/29/2018)
Has CELLECT BIOTECH/S been receiving favorable news coverage?
News coverage about APOP stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CELLECT BIOTECH/S earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of CELLECT BIOTECH/S's key competitors?
Some companies that are related to CELLECT BIOTECH/S include Co-Diagnostics (CODX), Dynatronics (DYNT), Valeritas (VLRX), Invivo Therapeutics (NVIV), Obalon Therapeutics (OBLN), United American Healthcare (UAHC), Neurometrix (NURO), Encision (ECIA), Cytori Therapeutics (CYTX), Calmare Therapeutics (CTTC), Regenicin (RGIN), Presbia (LENS), Amedica (AMDA), Delcath Systems (DCTH) and AdvanSource Biomaterials Corpration (ASNB).
What other stocks do shareholders of CELLECT BIOTECH/S own?
Who are CELLECT BIOTECH/S's key executives?
CELLECT BIOTECH/S's management team includes the folowing people:
- Mr. Kasbian Nuriel Chirich, Co-Founder & Exec. Chairman (Age 61)
- Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 61)
- Mr. Eyal Leibovitz, Chief Financial Officer (Age 58)
- Dr. Ronit Bakimer-Kleiner, Chief Devel. Officer (Age 57)
- Dr. Amos Ofer, VP of Operations (Age 43)
Who are CELLECT BIOTECH/S's major shareholders?
CELLECT BIOTECH/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (3.89%), Renaissance Technologies LLC (2.69%) and Wedbush Securities Inc. (1.19%).
Which major investors are buying CELLECT BIOTECH/S stock?
APOP stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Renaissance Technologies LLC and Wedbush Securities Inc..
How do I buy shares of CELLECT BIOTECH/S?
Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELLECT BIOTECH/S's stock price today?
One share of APOP stock can currently be purchased for approximately $0.70.
How big of a company is CELLECT BIOTECH/S?
CELLECT BIOTECH/S has a market capitalization of $3.81 million. CELLECT BIOTECH/S employs 28 workers across the globe.
What is CELLECT BIOTECH/S's official website?
How can I contact CELLECT BIOTECH/S?
CELLECT BIOTECH/S's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]
MarketBeat Community Rating for CELLECT BIOTECH/S (NASDAQ APOP)
MarketBeat's community ratings are surveys of what our community members think about CELLECT BIOTECH/S and other stocks. Vote "Outperform" if you believe APOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
